Search Results

Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”) today announced that the Company will make several presentations at the Clinical Trials at the Summit (CTS) Meeting being held in Park City, Utah on June 8, 2024.

Opthea Limited announced that the retail component of its 1 for 1.22 pro-rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Opthea and the issue of options to acquire fully paid ordinary shares in Opthea on a 1 for 3 basis to participants issued New Shares under the Retail Entitlement Offer.

Opthea Limited today announced that Dr. Frederic Guerard, Chief Executive Officer (CEO) of Opthea, will present the Company’s clinical-stage pipeline, as well as its innovation agenda, at the OIS Retina Innovation Summit prior to the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on May 4, 2024 in Seattle, Washington.

Opthea Limited today announced that it has now completed enrollment in both the COAST and ShORe trials constituting its pivotal Phase 3 clinical program.